Ultragenyx shares surge as blockbuster hopeful burosumab continues to perform in pivotal study
Just in time for its R&D day today, Ulytragenyx $RARE and its partners at Kyowa Hakko Kirin outlined updated 48 week data on burosumab, which is on track to get a likely FDA approval in the spring.
Moving the goal line out to 48 weeks, from 24, researchers say that 84% of patients suffering from X-linked hypophosphatemia — or XLH — and on the drug from the start of the trial hit their goal on serum phosphorus levels, which was the primary endpoint. And 89% of the switchovers from the placebo group also hit their marks on the biomarker for efficacy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
